Bioness Inc $8.9 Million Settlement for Breach of Fiduciary Duties in Merger

Bioness Inc. announced an $8.9 million class action settlement stemming from its 2021 merger with Bioventus Inc., a deal that affected investors who owned Bioness common stock as of March 30, 2021. The lawsuit alleged that key insiders associated with the Alfred E. Mann Trust—after the founder’s death—used their influence to steer the company into an “unfair” sale process. Plaintiffs claimed minority shareholders were disadvantaged, including by being required to sign a release of claims in order to receive their merger proceeds, and that other potential options for funding or acquiring the company were allegedly blocked or pushed aside. The case was filed in part because mergers in public companies have heightened legal duties: directors and controlling stakeholders must act in the best interests of the corporation and treat shareholders fairly when negotiating and approving a transaction. Here, the “fiduciary duty” allegations were significant because a breach can lead to claims that the sale process was improperly structured—potentially limiting what smaller holders could obtain and discouraging them from pursuing legal challenges. Settling, the defendants denied wrongdoing but agreed to pay to reduce the time and expense of litigation, and the settlement is expected to be distributed automatically (no claim form required) to eligible stockholders, including those who did not sign the letter of transmittal. Broader implications are similar to other merger-related shareholder disputes, often brought in Delaware’s Court of Chancery, where many U.S. corporate governance cases are handled and where rules governing class actions and fiduciary-duty standards are closely watched. The settlement is a “non-opt-out” class action under Delaware Court of Chancery Rules 23(a), 23(b)(i), and 23(b)(ii), reflecting how courts manage efficiency and consistency in shareholder remedy cases. For many investors, outcomes like this also underscore industry context: in regulated securities markets, merger terms and the documentation required to receive consideration (including releases and transmittal letters) are scrutinized, and settlements can signal risk management as much as an admission of fault—ending with court review through a scheduled fairness hearing on May 8, 2026.